How has been the historical performance of Trident Texofab?

Answer:The historical performance of Trident Texofab shows a steady growth in net sales and profit over the years, with notable fluctuations in costs and expenses.

Breakdown:
Trident Texofab's net sales have increased from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, reflecting a consistent upward trend. The total operating income followed a similar trajectory, rising from 84.29 Cr in Mar'22 to 122.06 Cr in Mar'25. However, the raw material costs peaked at 23.58 Cr in Mar'23 before declining to 18.68 Cr in Mar'25, while the purchase of finished goods also saw an increase from 34.09 Cr in Mar'21 to 89.02 Cr in Mar'25. Operating profit (PBDIT) fluctuated, reaching a high of 8.78 Cr in Mar'25, although it was lower than the previous year’s 8.21 Cr. Profit before tax showed variability, with a peak of 2.58 Cr in Mar'25. The profit after tax also increased to 2.51 Cr in Mar'25 from 1.08 Cr in Mar'24. On the balance sheet, total liabilities rose from 55.68 Cr in Mar'20 to 100.58 Cr in Mar'25, while total assets increased from 55.68 Cr to 100.58 Cr in the same period. The cash flow from operating activities turned negative in Mar'25 at -13.00 Cr, contrasting with positive cash flows in previous years, while financing activities generated a significant inflow of 36.00 Cr in Mar'25. Overall, Trident Texofab has demonstrated growth in sales and profits, despite challenges in managing costs and cash flows.